Foquest is now covered on the New Brunswick Formulary

Effective February 20, 2024, Foquest is listed on the New Brunswick Formulary (special authorization) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).

Learn more about the eligibility criteria for reimbursement of Foquest in New Brunswick.

The website is hand-crafted in ZippyHippo online marketing studio.